Overview

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.
Treatments:
Ketoconazole